AR095015A1 - Compuestos de azetidiniloxifenilpirrolidina - Google Patents

Compuestos de azetidiniloxifenilpirrolidina

Info

Publication number
AR095015A1
AR095015A1 ARP140100712A ARP140100712A AR095015A1 AR 095015 A1 AR095015 A1 AR 095015A1 AR P140100712 A ARP140100712 A AR P140100712A AR P140100712 A ARP140100712 A AR P140100712A AR 095015 A1 AR095015 A1 AR 095015A1
Authority
AR
Argentina
Prior art keywords
azetidinyloxyphenylpirrolidine
compounds
compound
formula
treat
Prior art date
Application number
ARP140100712A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR095015A1 publication Critical patent/AR095015A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente adicionalmente proporciona métodos de uso de un compuesto de fórmula (1) para tratar la vejiga sobrerreactiva. Reivindicación 1: Un compuesto de la fórmula (1) o una sal del mismo farmacéuticamente aceptable, caracterizado porque R es hidrógeno o metilo.
ARP140100712A 2013-03-13 2014-03-05 Compuestos de azetidiniloxifenilpirrolidina AR095015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361778546P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
AR095015A1 true AR095015A1 (es) 2015-09-16

Family

ID=50382705

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100712A AR095015A1 (es) 2013-03-13 2014-03-05 Compuestos de azetidiniloxifenilpirrolidina

Country Status (40)

Country Link
US (3) US9034864B2 (es)
EP (2) EP2970222B1 (es)
JP (2) JP6017708B2 (es)
KR (2) KR101702797B1 (es)
CN (2) CN105051034B (es)
AP (1) AP3850A (es)
AR (1) AR095015A1 (es)
AU (1) AU2014241444B2 (es)
BR (1) BR112015020222B1 (es)
CA (1) CA2899806C (es)
CL (1) CL2015002113A1 (es)
CR (1) CR20150417A (es)
CY (1) CY1120142T1 (es)
DK (1) DK2970222T3 (es)
DO (1) DOP2015000176A (es)
EA (1) EA026631B1 (es)
ES (1) ES2616470T3 (es)
HK (1) HK1212695A1 (es)
HR (1) HRP20170080T1 (es)
HU (1) HUE032235T2 (es)
IL (1) IL240904B (es)
JO (1) JO3264B1 (es)
LT (1) LT2970222T (es)
MA (1) MA38410B1 (es)
ME (1) ME02592B (es)
MX (1) MX2015012579A (es)
MY (1) MY180006A (es)
NZ (1) NZ710481A (es)
PE (1) PE20151669A1 (es)
PH (1) PH12015502032A1 (es)
PL (1) PL2970222T3 (es)
PT (1) PT2970222T (es)
RS (1) RS55594B1 (es)
SG (2) SG10201609717YA (es)
SI (1) SI2970222T1 (es)
TN (1) TN2015000384A1 (es)
TW (1) TWI617553B (es)
UA (1) UA115583C2 (es)
WO (1) WO2014159012A1 (es)
ZA (1) ZA201505417B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
WO2016033776A1 (en) * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
AR101696A1 (es) * 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
AU2019408336B2 (en) * 2018-12-18 2022-03-10 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Phenylpyrrolidine compound and use thereof
CN112409333A (zh) * 2019-08-23 2021-02-26 湖北生物医药产业技术研究院有限公司 苯基吡咯烷类化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp 3−フェニルピロリジン誘導体
DE19601938A1 (de) * 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
EA200300622A1 (ru) * 2001-01-31 2003-12-25 Пфайзер Продактс Инк. Производные амидов тиазолил-, оксазолил, пирролил- и имидазолилкислот, полезные в качестве ингибиторов изоферментов pde4
CA2623657A1 (en) 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
TW201206440A (en) * 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
MX2012013127A (es) * 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物

Also Published As

Publication number Publication date
HUE032235T2 (en) 2017-09-28
ES2616470T3 (es) 2017-06-13
JP6017708B2 (ja) 2016-11-02
US9034864B2 (en) 2015-05-19
PT2970222T (pt) 2017-02-08
ZA201505417B (en) 2022-09-28
EP3168216A1 (en) 2017-05-17
IL240904B (en) 2019-02-28
CA2899806A1 (en) 2014-10-02
KR20150119077A (ko) 2015-10-23
US20160122322A1 (en) 2016-05-05
JP2016510759A (ja) 2016-04-11
CR20150417A (es) 2015-09-16
BR112015020222B1 (pt) 2020-07-14
MA38410B1 (fr) 2016-09-30
TW201522327A (zh) 2015-06-16
CL2015002113A1 (es) 2016-01-15
NZ710481A (en) 2020-08-28
HRP20170080T1 (hr) 2017-03-10
MY180006A (en) 2020-11-19
JP2016216517A (ja) 2016-12-22
CN109336865A (zh) 2019-02-15
AU2014241444A1 (en) 2015-08-06
PE20151669A1 (es) 2015-11-12
PL2970222T3 (pl) 2017-06-30
BR112015020222A8 (pt) 2018-01-23
CA2899806C (en) 2017-07-18
AU2014241444B2 (en) 2016-04-07
DOP2015000176A (es) 2015-11-15
RS55594B1 (sr) 2017-06-30
ME02592B (me) 2017-06-20
SG11201507501YA (en) 2015-10-29
CN105051034B (zh) 2019-05-21
EA026631B1 (ru) 2017-04-28
SI2970222T1 (sl) 2017-02-28
MX2015012579A (es) 2016-01-20
KR20170013411A (ko) 2017-02-06
BR112015020222A2 (pt) 2017-07-18
KR101702797B1 (ko) 2017-02-06
IL240904A0 (en) 2015-10-29
TN2015000384A1 (en) 2017-01-03
UA115583C2 (uk) 2017-11-27
LT2970222T (lt) 2017-03-27
EP2970222A1 (en) 2016-01-20
US20150133423A1 (en) 2015-05-14
TWI617553B (zh) 2018-03-11
EP2970222B1 (en) 2016-12-21
WO2014159012A1 (en) 2014-10-02
CN105051034A (zh) 2015-11-11
PH12015502032A1 (en) 2016-01-18
US9604967B2 (en) 2017-03-28
HK1212695A1 (zh) 2016-06-17
US9266859B2 (en) 2016-02-23
MA38410A1 (fr) 2016-02-29
AP3850A (en) 2016-09-30
CY1120142T1 (el) 2018-12-12
DK2970222T3 (en) 2017-02-27
US20140275002A1 (en) 2014-09-18
SG10201609717YA (en) 2017-01-27
WO2014159012A9 (en) 2014-12-18
AP2015008699A0 (en) 2015-09-30
JP6204557B2 (ja) 2017-09-27
JO3264B1 (ar) 2018-09-16
KR101745304B1 (ko) 2017-06-08
EA201591498A1 (ru) 2015-12-30

Similar Documents

Publication Publication Date Title
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
AR108768A2 (es) Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
EA030199B9 (ru) Терапевтически активные соединения и способы их применения
AR103680A1 (es) Inhibidores selectivos de bace1
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
MX2016005760A (es) Inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
NI201800071A (es) Compuestos de isoindol
JO3742B1 (ar) مركب بيرانو داي بيريدين
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
EA201590656A1 (ru) Азаиндолины
DOP2016000062A (es) Derivados de indol-urea de glucopiranosil sustituido y su uso como inhibidores de sglt
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
AR097890A1 (es) Compuestos de urea
EA201501177A1 (ru) Фармацевтические композиции
AR108363A1 (es) Compuestos de tetrahidrofurooxazina y su uso como inhibidores de bace1 selectivos
PL405775A1 (pl) Nowy związek, zwłaszcza do stosowania jako pigment
GT201500232A (es) Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos

Legal Events

Date Code Title Description
FG Grant, registration